Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSichuan Provincial People's Hospital

About this trial

As infection control improves and circulation stabilizes, treatment de-escalation of septic shock begins, accompanied by fluid redistribution from interstitial spaces to the vasculature, increasing cardiac volume load. Synthetic recombinant human BNP (rh-BNP) plays a role in inducing vasodilation, particularly in the venous system, alleviating cardiac congestion, and enhancing natriuresis and diuresis. Thus the investigators designed a single-center, prospective physiological study to evaluate the efficacy of standard rh-BNP infusion in reducing venous return and enhancing fluid removal, with a secondary objective of assessing the maintenance of perfusion pressure and tissue perfusion.

Eligibility criteria

Qualifiers

Age >18 years.

Fulfilling the Sepsis-3 definition of septic shock at initial stage.

Hemodynamic stability achieved after adequate initial resuscitation and individualized hemodynamic optimization.

Controlled infection source with 48-hour trend of improving temperature, white blood cell count, and procalcitonin.

Disqualifiers

Pregnancy or lactation.

Arrhythmia.

Advanced renal dysfunction (Acute Kidney Injury [AKI] stage 3 or Chronic Kidney Disease [CKD] stage 3b or higher) based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria.

Inadequate ultrasound window preventing acquisition of diagnostic-quality images.

Trial design

Treatments tested in this trial

  • Lyophilized Recombinant Human Brain Natriuretic Peptide

Treatment groups

30 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Sichuan Provincial People's Hospital

Lead sponsor

Tibet Kangzhe Pharmaceutical Development Co., Ltd

Collaborator